Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Trevogrumab

Stage Phase 2

Sponsor Regeneron Pharmaceuticals

Sources

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT06299098

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE2. Lead sponsor Regeneron Pharmaceuticals. Enrollment 1005. Conditions Obesity. This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested. Part A of the

ClinicalTrials.gov NCT06299098 protocol and results modules

Studies

No trial is in this file.

Catalyst Studied in NCT06299098. The registry record names trevogrumab and garetosmab in one study. The study row is stored with garetosmab so the NCT id is not repeated.